Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS G12C Mutation Advanced Solid Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05358249
What this trial is testing

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung+8 more
Novartis Pharmaceuticals 74
Early research (Phase 1)Study completedNCT06117371
What this trial is testing

Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

Who this might be right for
Advanced or Metastatic Solid TumorKRAS G12C Mutation
BeBetter Med Inc 11
Testing effectiveness (Phase 2)UnknownNCT05119933
What this trial is testing

A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Who this might be right for
Advanced Solid Tumor
Shanghai YingLi Pharmaceutical Co. Ltd. 55
Testing effectiveness (Phase 2)Looking for participantsNCT05288205
What this trial is testing

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Who this might be right for
KRAS P.G12CNon-small Cell Lung CancerColorectal Cancer+1 more
Allist Pharmaceuticals, Inc. 240
Early research (Phase 1)UnknownNCT05768321
What this trial is testing

Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Who this might be right for
Advanced Solid Tumors
GenEros Biopharma Hangzhou Ltd 70
Testing effectiveness (Phase 2)Looking for participantsNCT06008288
What this trial is testing

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

Who this might be right for
KRAS P.G12CPancreatic CancerSolid Tumor
Allist Pharmaceuticals, Inc. 88
Early research (Phase 1)Looking for participantsNCT06917079
What this trial is testing

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Who this might be right for
Non-Small Cell Lung CancerNSCLCPDAC - Pancreatic Ductal Adenocarcinoma+11 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 665
Testing effectiveness (Phase 2)Looking for participantsNCT06973564
What this trial is testing

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

Who this might be right for
Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd. 294
Early research (Phase 1)Not Yet RecruitingNCT06594874
What this trial is testing

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd. 350
Early research (Phase 1)Study completedNCT06403436
What this trial is testing

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorAdult Solid TumorAdult Disease+5 more
TOLREMO therapeutics AG 45
Testing effectiveness (Phase 2)Study completedNCT05005234
What this trial is testing

GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

Who this might be right for
KRAS G12C
Innovent Biologics (Suzhou) Co. Ltd. 334
Testing effectiveness (Phase 2)Looking for participantsNCT06959615
What this trial is testing

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

Who this might be right for
Advanced Solid Tumor
Jacobio Pharmaceuticals Co., Ltd. 334
Testing effectiveness (Phase 2)UnknownNCT05993455
What this trial is testing

Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab

Who this might be right for
Efficacy
Korea University Anam Hospital 24
Early research (Phase 1)Looking for participantsNCT05067283
What this trial is testing

Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Who this might be right for
Advanced Solid Tumors
Merck Sharp & Dohme LLC 830
Early research (Phase 1)Looking for participantsNCT06026410
What this trial is testing

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Who this might be right for
Solid Tumors With HRAS AlterationsNon Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)+4 more
Kura Oncology, Inc. 300
Testing effectiveness (Phase 2)Looking for participantsNCT07209111
What this trial is testing

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

Who this might be right for
Neoplasm Malignant
Merck Sharp & Dohme LLC 150
Early research (Phase 1)UnknownNCT06006793
What this trial is testing

SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

Who this might be right for
Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD 50
Early research (Phase 1)Ended earlyNCT05480865
What this trial is testing

SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Who this might be right for
Solid Tumor, AdultMetastatic Solid TumorMetastatic NSCLC+1 more
Navire Pharma Inc., a BridgeBio company 28
Early research (Phase 1)Active Not RecruitingNCT04973163
What this trial is testing

Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Who this might be right for
Solid Tumors, KRAS Mutation
Boehringer Ingelheim 30
Early research (Phase 1)Looking for participantsNCT06983743
What this trial is testing

ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Metastatic Solid Tumors
Erasca, Inc. 600
Next Page